MX2014014105A - Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar). - Google Patents

Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar).

Info

Publication number
MX2014014105A
MX2014014105A MX2014014105A MX2014014105A MX2014014105A MX 2014014105 A MX2014014105 A MX 2014014105A MX 2014014105 A MX2014014105 A MX 2014014105A MX 2014014105 A MX2014014105 A MX 2014014105A MX 2014014105 A MX2014014105 A MX 2014014105A
Authority
MX
Mexico
Prior art keywords
pyrazole compounds
substituted pyrazole
compounds
lpar antagonists
lpar
Prior art date
Application number
MX2014014105A
Other languages
English (en)
Inventor
Yimin Qian
Matthew Michael Hamilton
Achyutharao Sidduri
Stephen Deems Gabriel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014014105(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014014105A publication Critical patent/MX2014014105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I): así como sales farmacéuticamente aceptables de los mismos, donde los sustituyentes son aquellos descritos en la descripción. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades y trastornos inflamatorios, tales como, por ejemplo, fibrosis pulmonar.
MX2014014105A 2012-06-20 2013-06-17 Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar). MX2014014105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
MX2014014105A true MX2014014105A (es) 2015-03-05

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014105A MX2014014105A (es) 2012-06-20 2013-06-17 Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar).

Country Status (22)

Country Link
US (1) US20150259295A1 (es)
EP (1) EP2864294A1 (es)
JP (1) JP2015520201A (es)
KR (1) KR20150011003A (es)
CN (1) CN104411690A (es)
AU (1) AU2013279510A1 (es)
BR (1) BR112014031108A2 (es)
CA (1) CA2869602A1 (es)
CL (1) CL2014003242A1 (es)
CO (1) CO7160077A2 (es)
CR (1) CR20140516A (es)
EA (1) EA201492283A1 (es)
HK (1) HK1206341A1 (es)
IL (1) IL236091A0 (es)
IN (1) IN2014DN09347A (es)
MA (1) MA37765A1 (es)
MX (1) MX2014014105A (es)
PE (1) PE20142445A1 (es)
PH (1) PH12014502364A1 (es)
SG (1) SG11201407229UA (es)
UA (1) UA109867C2 (es)
WO (1) WO2013189862A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
CA2953472C (en) 2014-06-27 2022-08-02 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
ES2962367T3 (es) * 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
IL298082A (en) 2020-06-03 2023-01-01 Gilead Sciences Inc lpa receptor antagonists and uses thereof
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022240879A1 (en) * 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249154A1 (en) * 2003-12-26 2008-10-09 Ono Pharmaceutical Co., Ltd. Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
JP2013501064A (ja) * 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
AU2011338561A1 (en) * 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
US8975235B2 (en) * 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors

Also Published As

Publication number Publication date
CR20140516A (es) 2014-12-01
WO2013189862A1 (en) 2013-12-27
CO7160077A2 (es) 2015-01-15
PH12014502364A1 (en) 2015-01-12
EP2864294A1 (en) 2015-04-29
CN104411690A (zh) 2015-03-11
AU2013279510A1 (en) 2014-10-16
EA201492283A1 (ru) 2015-04-30
BR112014031108A2 (pt) 2017-06-27
KR20150011003A (ko) 2015-01-29
CA2869602A1 (en) 2013-12-27
PE20142445A1 (es) 2015-01-28
SG11201407229UA (en) 2014-12-30
JP2015520201A (ja) 2015-07-16
MA37765A1 (fr) 2017-04-28
IL236091A0 (en) 2015-02-01
HK1206341A1 (en) 2016-01-08
US20150259295A1 (en) 2015-09-17
CL2014003242A1 (es) 2015-03-20
IN2014DN09347A (es) 2015-07-17
UA109867C2 (ru) 2015-10-12

Similar Documents

Publication Publication Date Title
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX354102B (es) Derivados de bencimidazol-prolina.
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MY175854A (en) Novel quinolone derivatives
IN2014MN02598A (es)
MX2016002794A (es) Compuestos antiproliferativos.
IN2015DN01119A (es)
WO2013004995A8 (en) Pyrimidinone compounds and their use
EA201600434A1 (ru) Применение производных бензимидазолпролина
UA117154C2 (uk) Антагоністи s1p3
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
PH12017501736A1 (en) Indole derivatives
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
UA112586C2 (uk) Похідні бензімідазолпроліну